Drug
Fxs5626
Fxs5626: highest development phase Phase 2, developed by Shanghai Fosun Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FXS5626 tablet NCT07552012 | Phase 2 | Active Non-anterior, Non-infectious Uveitis |
| FXS5626 tablet NCT07695779 | Phase 1 | Evaluation of QTc Interval |
Latest
No recent events.
Follow Fxs5626 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.